Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nobelpharma and Eisai have announced the launch of anticonvulsant agent, Fostoin 750mg for Injection (fosphenytoin sodium hydrate, fostoin), on 17 January 2012.
Subscribe to our email newsletter
Nobelpharma developed Fostoin in Japan. It will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.
Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used both in Japan and overseas as a treatment for status epilepticus and other such conditions.
By providing phenytoin as a water-soluble prodrug, the agent will reduce local irritation during intravenous infusion and is expected to enhance tolerability.